Thrombophilia and pregnancy

Current Pharmaceutical Design

Volumn 11, Issue 6, 2005, Pages 735-748

  Kupferminc, M J ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Fetal loss; Intrauterine growth restriction; Placental abruption; Preeclampsia; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; DIPYRIDAMOLE; ENOXAPARIN; FOLIC ACID; HEPARIN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; PYRIDOXINE;

ARTERY THROMBOSIS; CLINICAL TRIAL; DISEASE PREDISPOSITION; FEMALE; FETUS MORTALITY; FETUS WASTAGE; GENE MUTATION; GENETIC CODE; GENETIC RISK; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MATERNAL MORBIDITY; MATERNAL MORTALITY; PLACENTA CIRCULATION; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOLUTIO PLACENTAE; THROMBOPHILIA; VASCULAR DISEASE; VEIN THROMBOSIS;

ADULT; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; THROMBOPHILIA;

EID: 14844299318     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053381855     Document Type: Review

References (142)

1. Dahlback B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 1994; 24: 139-51.
2. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
3. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
5. Maertinelli I, Sagghi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in the user of oral contraceptives. N Engl J Med 1988; 338: 1793-7.
6. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
7. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocystinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
8. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-9.
9. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and Coronary Atherosclerosis. J Am Coll Cardiol 1996; 27: 517-27.
10. Sebastio G, Sperandeo MP, Panico M, de Franchis R, Kraus JP, Andria G. The molecular basis of homocysteinuria due to cystathionie beta-synthase deficiency in Italian families, and report for four novel mutations. Am J Hum Genet 1995; 56: 1324-33.
11. Roberts JM, Taylor RN, Musici TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-4.
12. Salafia CM, Pezzulo JC, Lopez-Zeno JA, Minior VK, Vintzileos AM. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995; 173: 1079-1105.
13. Shanklin DR, Sibai BM. Ultrastructural aspects of preeclampsia. Am J Obstet Gynecol 1989; 161: 735-41.
14. Khong TY, Pearce JM, Robertson WB. Acute atherosis in preeclampsia: maternal determination and fetal outcome in the presence of the lesion. Am J Obstet Gynecol 1987; 157: 360-3.
15. Salafia CM, Minior VK, Pezzulo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features Am J Obstet Gynecol 1995; 173: 1049-57.
16. Greer IA. Thrombosis in Pregnancy: Maternal and Fetal Issues. Lancet 1999; 353: 1258-65.
17. Seligsohn U, Zivelin A. Thrombophilia As a Multigenic Disorder. Thromb Haemost 1997; 78: 297-301.
18. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, et al. Prothrombin and Factor V Mutations in Women With a History of Thrombosis During Pregnancy and the Puerperium. N Engl J Med 2000; 342: 374-80.
19. Greer IA. The Challenge of Thrombophilia in Maternal-Fetal Medicine. N Engl J Med 2000; 342: 424-5.
20. Green JR. Placenta previa and abruptio placentae. In: Creasy RK, Resnik R. eds, Maternal Fetal Medicine: Principles and Practice. Philadelphia: WB Saunders Co. 1994; 609-10.
21. Infante-Rievard C, David M, Gauthier R, Ribard GE. Lupus anticoagulants, anticardiolipin antibodies and fetal loss. N Engl J Med 1991; 325: 1063-6.
22. Dekker GA, Sibai BM. Etiology and pathophysiology of preeclampsia: Current concepts. Am J Obstet Gynecol. 1998; 179: 1359-1375. Review.
23. Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 2001; 98: 1041-4.
24. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 2000; 15: 1830-3
25. Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, Nikkels PG. Placental pathology in early onset pre-eclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta 2002; 23: 337-42.
26. Arias F, Romero R, Joist H, Kraus FT. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med 1998; 7: 277-86.
27. Alarcon-Segovia D, Delete M, Oria CV, Sanchez-Guerrero J, Gomet-Pacheco L, Cabiedes I, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine 1989; 68: 353-365.
28. Asherson RA, Khamashta MA, Ordi-RosJ, Derksen RH, Machin SJ, Barquinerol, et al. The "primary" anti-phospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366-374.
29. Harris EN. Syndrome of the black swan. Br J Rheumatol 1987; 26: 324-326.
30. Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J. Pregnancy loss in the antiphospholid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997; 337: 154-160.
31. Branch DW, Silver RM, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and anliphospholipid syndrome. Obstet Gynecol 1997; 89: 549-555.
32. MacLean MA, Cumming GP, McCall F, Walker ID, Wallter JJ. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994; 101: 103-110.
33. Out HJ, Bruinse HW, Christiaens GC, van Vliet M, Meilof IF, de Groot PG, et al. Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann Rheum Dis 1991; 50: 553-557.
34. Parazzini F, Acaia B, Faden D, Lovotti M, Marelli G, Cortelazzo S. Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol 1991; 77:854-858.
35. Petri M, Golbus M, Anderson R, Whiting-O'Keefe Q, Corash L, Hellmann D. Antinuclear antibody, lupus antiroagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled prospective study of forty-four women. Arthritis Rheum 1987; 30: 601606.
36. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996; 66: 540-546.
37. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10: 3301-3304.
38. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87: 489-493.
39. Bocciolone L, Meroni P, Parazrini F, Tincani A, Radici E, Tarantini M, et al. Antiphospholipid antibodies and risk of inuauterine late fetal death. Acta Obstet Gynecol Scand 1994; 73: 389-392.
40. Branch DW, Silver RM, Blackwell IL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80: 614-620.
41. Scott RA. Anti-cardiolipin antibodies and pre-eclampsia. Br J Obstet Gynaecol 1987; 94: 604-605.
42. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989; 73: 541-545.
43. Dekker GA, de Vries JI, Doelitzsch PM, Huijgens PC, Blomberg von BM, Jakobs C, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-1048.
44. Pampus van MG, MP van, Dekker GA, Wolf HW, PC Huijgens PC, Koopman MM, Blomberg BM von, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146-1150.
45. Pattison NS, Chamley LW, McKay W, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993; 100: 909-913.
46. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995; 86: 555-559.
47. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of the genetic thrombophilia in women with complications of pregnancy. N Eng J Med 1999; 340: 9-13.
48. Rajah SB, Moodley J, Pudifin D, Duursma J. Anticardiolipin antibodies in hypertensive emergencies. Clin. and Exper.-Hypertension in Pregnancy 1990; B9: 267-271.
49. Out HJ, Bruinse HW, Christiaens GC, Van Vliet M, De Groot PG, Nieuwenhuis HK, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26-20.
50. Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994; 120: 470-475.
51. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with lupus anticoagulant. N Engl J Med 1985; 313: 1322-1326.
52. Caruso A, De Carolis S, Ferrazzani S, Valesini G, Caforio L, Manusco S. Pregnancy outcome in relation to uterine artery now velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. Obstet Gynecol 1993; 82: 970-976.
53. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BI, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 131-136.
54. Polzin WJ, Kopelman JN, Robinson RD, Read JA, Brady K. The association of antiphospholipid antibodies with pregnancy complicated by fetal growth restriction. Obstet Gynecol 1991; 78: 1108-1111.
55. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902-5.
56. Nagy B, Tóth T, Rigó J Jr, Karádi I, Romics L, Papp Z. Detection of factor v Leiden in severe pre-eclamptic Hungarian women. Clin Genet 1998; 53: 478-81.
57. Rigo J Jr, Nagy B, Fintor L, Tanyi J, Beke A, Karadi I, et al. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetrahydrofolate reductase. Hypertens Pregnancy. 2000; 19: 163-72.
58. Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000; 96: 45-9.
59. von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden mutation, coagulation inhibitor deficiency, and elevated antiphospholipid antibodies in patients with pre-eclampsia or HELLP-syndrome. Thromb Res 2000; 100: 363-5. 2000; 50: 254-752.
60. Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001; 185: 153-7.
61. Laivuori H, Kaaja R, Ylikorkala O, Hiltunen T, Kontula K. 677C.T polymorphism of the MTHFR gene and pre-eclampsia. Obstet Gynecol 2000; 96: 277-80.
62. Higgins JR, Kaiser T, Moses EK, North R, Brennecke SP. Prothrombin G20210A mutation: is it associated with pre-eclampsia? Gynecol Obstet Invest 2000; 50: 254-56.
63. Kupfern MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and 2nd trimester loss. Acta Obstet Gynecol Scand 2000; 79: 963-7.
64. Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol1998; 92: 457-60.
65. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini D, Martinelli P, et al. Factor V Leiden, C >T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997; 77: 1052-4.
66. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Scianname N, Montanaro S, et al. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria. Thromb Haemost 1999; 81: 349-52.
67. O'Shaughnessy KM, Fu B. Ferraro F, Lewis I, Downing S, Morris NH. Factor V Leiden and thermolable methylenetetrahydrofolate reductase gene variants in an east Anglian preeclampsia cohort. Hypertension 1999; 33: 1338-1341.
68. Sohda S, Arinami T, Hamada HM, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997; 34: 525-6.
69. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with reduced response to activated protein C. Am J Obstet Gynecol 1997; 176 :457-60.
70. Mello G, Parretti E, Martini E, Mecacci F, La Torre P, Cioni R, et al. Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies. Haemostasis 1999; 29: 197-203.
71. Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532-7.
72. De Groot CJ, Bloemenkamp KW, Duvekot EJ, Helmerhorst FM, Bertina RM, Van Der Meer F, et al. Preeclampsia and genetic risk factors for thrombosis: a casecontrol study. Am J Obstet Gynecol 1999; 181: 975-80.
73. Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-Review.
74. Murphy RP, Donoghue C, Nallen RJ, D'Mello M, Regan C, Whitehead AS, et al. Prospective evaluation of the risk conferred by factor V Leiden and the thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20: 266-70.
75. Kim YJ, Williamson RA, Murray JC, Andrews J, Pietscher JJ, Peraud PJ, et al. Genetic susceptibility to pre-eclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-basepair insertion at nucleotide 844 of the gene for cystathione β-synthase, and factor V Leiden mutation. Am J Obstet Gynecol 2001; 184: 1211-7.
76. Powers RW, Minich LA, Lykins DL, Ness RB, Crombleholme WR, Roberts JM. Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Invest 1999; 6: 74-9.
77. Lachmeijer AM, Arngrimsson R, Bastiaans EJ, Pals G, ten Kate LP, de Vries JI, et al. Mutations in the gene for MTHFR, homocysteine levels, and vitamin status in women with a history of PE. Am J Obstet Gynecol 2001; 184: 394-402.
78. Zusterzeel PL, Visser W, Blom HJ, Peters WH, Heil SG, Steegers EA. Methylenetetrahydrofolate reductase polymorphisms in preeclampsia and the HELLP syndrome. Hypertens Preg 2000; 19: 299-307.
79. Kaiser T, Brennecke SP, Moses EK. Methylenetetrahydrofolate reductase polymorphisms are not a risk factor for preeclampsia/eclampsia in Australian women. Gynecol Obstet Invest 2000; 50: 100-2.
80. Hague B, Wiltshire E, Nelson P, Dekker G, Robinson J, Thomas D. Polymorphisms of Methylenetetrahydrofolate reductase in women with pre-eclampsia. Hypertens Pregnancy 2000; 19: 23.
81. Rajkovic A, Catlano PM, Malinow MR. Elevated homocysteine levels with preeclampsia. Obstet Gynecol 1997; 90: 168-71.
82. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 2000; 71: 962-8.
83. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. Am J Obstet Gynecol 2001; 185: 781-5.
84. Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK, et al: The 4G/4G polymorphism of the hypofibrinolytic PAI-1 gene: an independent risk factor for serious pregnancy complications. Metabolism 2000; 49: 845-852.
85. Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Eldor A. Increased Frequency of the Hypofibrinolytic 4G/4G Polymorphism of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene in Women with Obstetric Complications. Obstet Gynecol 2001; 97: 44-48.
86. Sibai BM, Ramadan MK, Chari RS, Friedman SA. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes,and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 1995; 172: 125-9.
87. Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 2002; 186: 422-6.
88. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am.J.Obstet.Gynecol 1991; 165: 1408-1412.
89. de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocystinemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997; 104: 1248-54.
90. Martinelli P, Grandone E, Colaizzo D, Paladini D, Scianname N, Margaglione M, et al. Familial thrombophilia and the occurrence of fetal growth restriction. Hematologica 2001; 86: 428-431.
91. Grandone E, Margaglione M, Colaizzo D, Pavone G, Paladini D, Martinelli P, et al. Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A (20210) mutations Hematologica 2002; 87: 177-181.
92. Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, et al. Absence of Association of Thrombophilia Polymorphisms with Intrauterine Growth Restriction. N Engl J Med 2002; 347: 19-25.
93. Reznik R. Intrauterine growth restriction. Obstet Gynecol 2002; 99: 490-496.
94. Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Landsberg JA. Mid-Trimester Severe intrauterine growth restriction Is Associated with a high Prevalence of Thrombophilia. Br J Obstet Gynaecol 2002; 109: 1373-6.
95. van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. Br J Obstet Gynaecol 2000; 107: 785-91.
96. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol 1998; 179: 1565-7.
97. Goddijn-Wessel TA, Wouters MG, van de Molen EF, Spuijbroek MD, Steegers-Theunissen RP, Blom HJ, et al. Hyperhomocystinemia: a risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol 1996; 66: 23-9.
98. Regan L, Rai R. Thrombophilia and pregnancy loss. J Reprod Immunol 2002; 55: 163-80. Review.
99. Tulppala M, Viinikka L, Ylikorkaka O. Thromboxane dominance and prostacyclin deficiency in habitual abortion. Lancet 1991; 387: 879-81.
100. Vincent T, Rai R, Regan L Cohen H. Increased thrombin generation in non pregnant women with recurrent miscarriage. Lancet 1998; 352: 116.
101. Woodhams BJ, Candotti G, Shaw R, Kernoff PB. Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb Res 1989; 55: 99-107.
102. Rai R, Tuddenham E, Backos M, Regan L. Pre-pregnancy thrombophilic abnormalities are associated with subsequent spontaneous abortion. Hum. Reprod 2000; 15: 168.
103. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589.
104. Rai R, Cohen H, Dave M, Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) BMJ 1997; 314: 253-257.
105. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82: 6-9.
106. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97: 551-4.
107. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 1000-3.
108. Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 2000; 43: 31-5.
109. Sarig G, Younis JS, Hoffman R, Lanir N, Blumenfeld Z, Brenner B. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002; 77: 342-7.
110. Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 1999; 14: 1624-7.
111. Finan RR, Tamim H, Ameen G, Sharida HE, Rashid M, Almawi WY. Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. Am J Hematol 2002; 71: 300-5.
112. Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida A, Agorastos T, et al. Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000; 15: 458-62.
113. Reznikoff-Etievan MF, Cayol V, Carbonne B, Robert A, Coulet F, Milliez J. Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. Br J Obstet Gynaecol 2001; 108: 1251-4.
114. Alonso A, Soto I, Urgelles MF, Corte JR, Rodriguez MJ, Pinto CR. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol 2002; 187: 1337-42.
115. Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K, et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16: 961-5.
116. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77: 822-4.
117. Kutteh WH, Park VM, Deitcher SR. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril 1999; 71: 1048-53.
118. Dizon-Townson DS, Kinney S, Branch DW, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997; 34: 217-23.
119. Deitcher SR, Park VM, Kutteh WH. Methylene tetrahydrofolate reductase 677C T mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood 1998; 92(Suppl 1): 117b.
120. Kornberg A, Raziel A, Rahimini-Levene N, Yona R, Sela BA, Ron-El R. Hypcrcoagulability and recurrent abortions. Blood 1998; 92(Suppl 1): 121b.
121. Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers CH, Eskes TK. Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr 1998; 128: 1336-1341.
122. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: a metaanalysis. Fertil Steril 2000; 74: 1196-9.
123. Souza SS, Ferriani RA, Pontes AG, Zago MA, Franco RF. Factor V leiden and factor II G20210A mutations in patients with recurrent abortion. Hum Reprod 1999; 14: 2448-50
124. Pickering W, Holmes Z, Regan L, Cohen H. Normal prevalence of the G20210A prothrombin gene mutation in women with recurrent miscarriage. Br J Haematol 1998; 102: 250.
125. Deitcher SR, Park VM, Kutteh WH. Prothrombin 20210 G A mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood 1998; 92(Suppl 1): 118b.
126. Pihusch R, Buchholz T, Lohse P, Rubsamen H, Rogenhofer N, Hasbargen U, et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001; 46: 124-31.
127. Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75: 387-8.
128. Brenner B. Inherited thrombophilia and fetal loss. Curr Opin Hematol 2000; 7: 290-5. Review.
129. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
130. Gris JC, Quere I, Monpeyroux F, Mercier E, Ripart-Neveu S, Tailland ML, et al. Case-control study of the frequency of thrombophilic disorders in couples with late foctal loss and no thrombotic antecedent - the Nimes Obstetricians and Haematologists Study5 (NOHA5). Thromb Haemost 1999; 81: 891-9.
131. Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-8.
132. Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ. Third-trimester unexplained intrauterine fetal death is associated with inherited thromhophilia. Obstet Gynecol 2002; 99: 684-7.
133. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-7.
134. Younis JS, Ohel G, Brenner B, Haddad S, Lanir N, Ben-Ami M. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. Br J Obstet Gynaecol 2000; 107: 415-9.
135. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 2001; 322: 329-33. Review.
136. North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol 1995; 35: 357-62.
137. Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, et al. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertension in Pregnancy 2001; 20: 35-44.
138. Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998; 80: 49-54.
139. Leeda M, Riyazi N, de Vries JI, Jakobs C, van Geijn HP, Dekker GA. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol 1998; 179: 135-9.
140. Ahn HS, Chackalamannil S, Boykow G, Graziano MP, Foster C. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Curr Pharm Design 2003; 9(28): 2349-65.
141. Hertelendy F, Zakar T. Regulation of myometrial smooth muscle functions. Curr Pharm Design 2004; 10(20): 2499-517.
142. Maul H, Longo M, Saade GR, Garfield RE. Nitric oxide and its role during pregnancy: from ovulation to delivery. Curr Pharm Design 2003; 9(5): 359-80.